Helicobacter pylori eradication: Novel therapy for immune thrombocytopenic purpura? A review of the literature

American Journal of Hematology

Volumn 78, Issue 2, 2005, Pages 142-150

  Jackson, Shannon ^a,b   Beck, Paul L ^a   Pineo, Graham F ^a   Poon, Man Chiu ^a  

^a UNIVERSITY OF CALGARY   (Canada)

^b FOOTHILLS HOSPITAL   (Canada)

Author keywords

Helicobacter pylori; Immune thrombocytopenic purpura

Indexed keywords

CORTICOSTEROID; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; MACROLIDE; PROTON PUMP INHIBITOR;

ANTIBIOTIC THERAPY; COHORT ANALYSIS; DISEASE ACTIVITY; ERADICATION THERAPY; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOMODULATION; ITALY; JAPAN; MOLECULAR MIMICRY; POPULATION RESEARCH; PRIORITY JOURNAL; REVIEW; SPLENECTOMY; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; PLATELET AGGREGATION; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC;

EID: 13244272112     PISSN: 03618609     EISSN: None     Source Type: Journal    
DOI: 10.1002/ajh.20250     Document Type: Review

References (93)

1. Suerbaum S, Michetti P. Helicobacter pylori infection. N Engl J Med 2002;347:1175-1186.
2. Blaser MJ. The genetic gymnastics of our indigenous microbes. N Engl J Med 2002;346:2083-2085.
3. Graham DY. NSAIDs, Helicobacter pylori, and Pandora's box. N Engl J Med 2002;347:2162-2164.
4. Figura N. Sjögren's syndrome and Helicobacter pylori infection. Eur J Gastroenterol Hepatol 1994;6:321-322.
5. Giordano N, Figura N, Senesi M, et al. Helicobacter pylori infection and primary Sjögren's syndrome: a possible association and new therapeutic approach. Curr Ther Res 1995;56:1265-1269.
6. Zentilin P, Seriolo B, Dulbecco P, et al. Eradication of Helicobacter pylori may reduce disease severity in rheumatoid arthritis. Aliment Pharmacol Ther 2002;16:1291-1299.
7. Annibale B, Lahner E, Bordi C, et al. Role of Helicobacter pylori infection in pernicious anaemia. Dig Liver Dis 2000;32:756-762.
8. Gupta V, Eden AJ, Mills MJ. Helicobacter pylori and autoimmune neutropenia. Clin Lab Haematol 2002;24:183-185.
9. Birnie DH, Holme ER, McKay IC, Hood S, McColl KE, Hillis WS. Association between antibodies to heat shock protein 65 and coronary atherosclerosis. Possible mechanism of action of Helicobacter pylori and other bacterial infections in increasing cardiovascular risk. Eur Heart J 1998;19:387-394.
10. Pasceri V, Cammarota G, Patti G, et al. Association of virulent Helicobacter pylori strains with ischemic heart disease. Circulation 1998;97:1675-1679.
11. Figura N, Di Cairano G, Lore F, et al. The infection by Helicobacter pylori strains expressing CagA is highly prevalent in women with autoimmune thyroid disorders. J Physiol Pharmacol 1995;50:817-826.
12. Machet L, Vaillant L, Machet MC, Buchler M, Lorette G. Schönlein-Henoch purpura associated with gastric Helicobacter pylori infection. Dermatology 1997;194:86.
13. Ando K, Shimamoto T, Tauchi T, et al. Can eradication therapy for Helicobacter pylori really improve the thrombocytopenia in idiopathic thrombocytopenic purpura? Our experience and a literature review. Int J Hematol 2003;77:239-244.
14. Emilia G, Longo G, Luppi M, et al. Helicobacter pylori eradication can induce platelet recovery in idiopathic thrombocytopenic purpura. Blood 2001;97:812-814.
15. Emilia G, Luppi M, Morselli M, Potenza L, D'Apollo N, Torelli G. Helicobacter pylori infection and idiopathic thrombocytopenic purpura. Br J Haematol 2002;118:1198-1199.
16. Garcia Perez A, Valverde de La Osa J, Gimenez Samper M, Alonso Garcia I. Resolution of an autoimmune thrombocytopenic purpura after eradicating treatment of Helicobacter pylori. Sangre (Barc) 1999;44:387-388 [article in Spanish].
17. Goto H, Kikuta T, Ota A, Tsuji H, Hino R. Successful treatment of refractory idiopathic thrombocytopenic purpura by eradication of Helicobacter pylori. Rinsho Ketsueki 2001;42:1192-1194 [article in Japanese].
18. Grimaz S, Damiani D, Brosolo P, Skert C, Geromin A, de Pretis G. Resolution of thrombocytopenia after treatment for Helicobacter pylori: a case report. Haematologica 1999;84:283-284.
19. Hashino S, Mori A, Suzuki S, et al. Platelet recovery in patients with idiopathic thrombocytopenic purpura after eradication of Helicobacter pylori. Int J Hematol 2003;77:188-191.
20. Hino M, Yamane T, Park K, et al. Platelet recovery after eradication of Helicobacter pylori in patients with idiopathic thrombocytopenic purpura. Ann Hematol 2003;82:30-32.
21. Kohda K, Koike K, Kuga T, Kuroiwa G, Sakurai T, Nakazawa O. Remission of idiopathic thrombocytopenic purpura after eradication of Helicobacter pylori: report of two cases. Nippon Naika Gakkai Zasshi 2001;90:2069-2070 [article in Japanese].
22. Kohda K, Kuga T, Kogawa K, et al. Effect of Helicobacter pylori eradication on platelet recovery in Japanese patients with chronic idiopathic thrombocytopenic purpura and secondary autoimmune thrombocytopenic purpura. Br J Haematol 2002;118:584-588.
23. Kohda K, Niitsu Y. Helicobacter pylori infection and idiopathic thrombocytopenic purpura. Nippon Rinsho 2003;61:644-649 [article in Japanese].
24. Michel M, Cooper N, Jean C, Frissora C, Bussel JB. Does Helicobacter pylori initiate or perpetuate immune thrombocytopenic purpura? Blood 2004;103(3):890-896 (Epub ahead of print 14 August 2003).
25. Rajantie J, Klemola T. Helicobacter pylori and idiopathic thrombocytopenic purpura in children. Blood 2003;101:1660.
26. Tohda S, Ohkusa T. Resolution of refractory idiopathic thrombocytopenic purpura after eradication of Helicobacter pylori. Am J Hematol 2000;65:329-330.
27. Veneri D, Franchini M, Gottardi M, et al. Efficacy of Helicobacter pylori eradication in raising platelet count in adult patients with idiopathic thrombocytopenic purpura. Haematologica 2002;87:1177-1179.
28. Gasbarrini A, Franceschi F, Tartaglione R, Landolfi R, Pola P, Gasbarrini G. Regression of autoimmune thrombocytopenia after eradication of Helicobacter pylori. Lancet 1998;352:878.
29. Takahashi T, Yujiri T, Shinohara K, et al. Molecular mimicry by Helicobacter pylori CagA protein may be involved in the pathogenesis of H. pylori-associated chronic idiopathic thrombocytopenic purpura. Br J Haematol 2004;124:91-96.
30. Asaumi N, Niiya K, Shibakura M, Yoshida C, Niya M, Tanimoto M. Secondary eradication of Helicobacter pylori was effective against refractory idiopathic thrombocytopenic purpura. Blood Coagul Fibrinolysis 2003;14:785-786.
31. George JN, Woolf SH, Raskob GE, et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood 1996;88:3-40.
32. Cines DB, Blanchette VS. Immune thrombocytopenic purpura. N Engl J Med 2002;346:995-1008.
33. Bettaieb A, Fromont P, Louache F, et al. Presence of cross-reactive antibody between human immunodeficiency virus (HIV) and platelet glycoproteins in HIV-related immune thrombocytopenic purpura. Blood 1992;80:162-169.
34. Scaradavou A. HIV-related thrombocytopenia. Blood Rev 2002;16:73-76.
35. Pockros PJ, Duchini A, McMillan R, Nyberg LM, McHutchison J, Viernes E. Immune thrombocytopenic purpura in patients with chronic hepatitis C virus infection. Am J Gastroenterol 2002;97:2040-2045.
36. Zhang L, Li H, Zhao H, Ji L, Yang R. Hepatitis C virus-related adult chronic idiopathic thrombocytopenic purpura: experience from a single Chinese center. Eur J Haematol 2003;70:196-197.
37. Pamuk GE, Pamuk ON, Baslar Z, et al. Overview of 321 patients with idiopathic thrombocytopenic purpura. Retrospective analysis of the clinical features and response to therapy. Ann Hematol 2002;81:436-440.
38. Funauchi M, Hamada K, Enomoto H, et al. Characteristics of the clinical findings in patients with idiopathic thrombocytopenic purpura who are positive for anti-phospholipid antibodies. Intern Med 1997;36:882-885.
39. Fabris F, Steffan A, Cordiano I, et al. Specific antiplatelet autoantibodies in patients with antiphospholipid antibodies and thrombocytopenia. Eur J Haematol 1994;53:232-236.
40. Portielje JE, Westendorp RG, Kluin-Nelemans HC, Brand A. Morbidity and mortality in adults with idiopathic thrombocytopenic purpura. Blood 2001;97:2549-2554.
41. van Leeuwen EF, van der Ven JT, Engelfriet CP, von dem Borne AE. Specificity of autoantibodies in autoimmune thrombocytopenia. Blood 1982;59:23-26.
42. He R, Reid DM, Jones CE, Shulman NR. Spectrum of Ig classes, specificities, and titers of serum antiglycoproteins in chronic idiopathic thrombocytopenic purpura. Blood 1994;83:1024-1032.
43. Kunicki TJ, Newman PJ. The molecular immunology of human platelet proteins. Blood 1992;80:1386-1404.
44. Coopamah MD, Garvey MB, Freedman J, Semple JW. Cellular immune mechanisms in autoimmune thrombocytopenic purpura: an update. Transfus Med Rev 2003;17:69-80.
45. Kuwana M, Kaburaki J, Kitasato H, et al. Immunodominant epitopes on glycoprotein IIb-IIIa recognized by autoreactive T cells in patients with immune thrombocytopenic purpura. Blood 2001;98:130-139.
46. + cells from autoimmune thrombocytopenic purpura (ATP) patients: their implication in the clinical course of the disease. Am J Hematol 1995;49:271-276.
47. Panitsas F, Theodoropoulou M, Kouraklis A, et al. Adult chronic idiopathic thrombocytopenic purpura (ITP) is the manifestation of a type-1 polarized immune response. Blood 2004;103(7):2645-2647 (Epub ahead of print 11 December 2003).
48. Semple JW, Milev Y, Cosgrave D, et al. Differences in serum cytokine levels in acute and chronic autoimmune thrombocytopenic purpura: relationship to platelet phenotype and antiplatelet T-cell reactivity. Blood 1996;87:4245-4254.
49. Kuwana M, Okazaki Y, Kaburaki J, Kawakami Y, Ikeda Y. Spleen is a primary site for activation of platelet-reactive T and B cells in patients with immune thrombocytopenic purpura. J Immunol 2002;168:3675-3682.
50. Iwabe K, Teramura M, Masuda M, Motoji T, Mizoguchi M. Proton pump inhibitors can increase platelet counts in patients with idiopathic thrombocytopenic purpura (ITP). American Society of Hematology Annual Meeting, Philadelphia, PA, 2002. Abstract 3798.
51. Kumagai T, Sekigawa K, Hashimoto N, Shirato R. Remission of idiopathic thrombocytopenic purpura by eradicating Helicobacter pylori after omeprazole monotherapy. Int J Hematol 2001;74:237-238.
52. Soldinger E, Pilia MC, Piubello W, Nadali G. Multi-resistant idiopathic thrombocytopenia successfully treated by eradication of Helicobacter pylori. Dig Liver Dis 2001;33:732.
53. Mukai M, Kon Y, Notoya A, Kohno M. Helicobacter pylori associated with idiopathic thrombocytopenic purpura. Am J Med 2002;113:169-171.
54. Nomura S, Inami N, Kanazawa S. The effects of H. pylori eradication on chemokine production in patients with immune thrombocytopenic purpura. Eur J Haematol 2004;72:304-305.
55. Veneri D, Krampera M, Franchini M. Helicobacter pylori infection and idiopathic thrombocytopenic purpura: description of 21 newly diagnosed cases. Haematologica 2004;89:ECR08 (e-case report).
56. Michel M, Cooper N, Jean C, Frissora C, Bussel JB. Does Helicobacter pylori initiate or perpetuate immune thrombocytopenic purpura? Blood 2004;103:890-896.
57. Jarque I, Andreu R, Llopis I, et al. Absence of platelet response after eradication of Helicobacter pylori infection in patients with chronic idiopathic thrombocytopenic purpura. Br J Haematol 2001;115:1002-1003.
58. McMillan R. Autoantibodies and autoantigens in chronic immune thrombocytopenic purpura. Semin Hematol 2000;37:239-248.
59. Fukuda Y. Suppression of Helicobacter pylori colonization with omeprazole. Scand J Gastroenterol 1996;31(Suppl 214):54-55.
60. Meyer-Rosberg K, Scott DR, Rex D, Melchers K, Sachs G. The effect of environmental pH on the proton motive force of Helicobacter pylori. Gastroenterology 1996;111:886-900.
61. Michel M, Khellaf M, Desforges L, et al. Autoimmune thrombocytopenic purpura and Helicobacter pylori infection. Arch Intern Med 2002;162:1033-1036.
62. Jaing T-H, Yang C-P, Hung I-J. Efficacy of Helicobacter pylori eradication on platelet recovery in children with chronic idiopathic thrombocytopenic purpura. Acta Paediatr 2003;92:1153-1157.
63. Veneri D, Gottardi M, Guizzardi E, Zanuso C, Krampera M, Franchini M. Idiopathic thrombocytopenic purpura, Helicobacter pylon infection, and HLA class II alleles. Blood 2002;100:1925-1926; author reply 1926-1927.
64. Franceschi F, Genta RM, Gasbarrini A, Gentiloni Silveri N, Gasbarrini G, Sepulveda AR. Helicobacter pylori infection and expression of the angiogenic factor platelet-derived endothelial cell growth factor by pre-neoplastic gastric mucosal lesions and gastric carcinoma. Dig Liver Dis 2002;34:621-625.
65. Provan D, Newland A, Norfolk D, et al. Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy. Br J Haematol 2003;120:574-596.
66. Blaser MJ. The versatility of Helicobacter pylori in the adaptation to the human stomach. J Physiol Pharmacol 1997;48:307-314.
67. Falush D, Kraft C, Taylor NS, et al. Recombination and mutation during long-term gastric colonization by Helicobacter pylori: estimates of clock rates, recombination size and minimal age. Proc Natl Acad Sci U S A 2001;98:15056-15061.
68. Suerbaum S, Smith JM, Bapumia K, et al. Free recombination within Helicobacter pylori. Proc Natl Acad Sci USA 1998;95:12619-12624.
69. Go MF. Review article: natural history and epidemiology of Helicobacter pylori infection. Aliment Pharmacol Ther 2002;16 (Suppl 1):3-15.
70. Malaty HM, Graham DY. Importance of childhood socioeconomic status on the current prevalence of Helicobacter pylori infection. Gut 1994;35:742-745.
71. Katelaris PH, Tippett GH, Norbu P, Lowe DG, Brennan R, Farthing MJ. Dyspepsia, Helicobacter pylori, and peptic ulcer in a randomly selected population in India. Gut 1992;33:1462-1466.
72. Reshetnikov OV, Haiva VM, Granberg C, Kurilovich SA, Babin VP. Seroprevalence of Helicobacter pylori infection in Siberia. Helicobacter 2001;6:331-336.
73. Blecker U, Lanciers S, Hauser B, Vandenplas Y. Helicobacter pylori positivity in Belgium. Acta Gastroenterol Belg 1995;58:31-34.
74. Lane JA, Harvey RF, Murray LJ, et al. A placebo-controlled randomized trial of eradication of Helicobacter pylori in the general population: study design and response rates of the Bristol Helicobacter Project. Control Clin Trials 2002;23:321-332.
75. Everhart JE, Kruszon-Moran D, Perez-Perez GI, Tralka TS, McQuillan G. Seroprevalence and ethnic differences in Helicobacter pylori infection among adults in the United States. J Infect Dis 2000;181:1359-1363.
76. Graham DY, Malaty HM, Evans DG, Evans DJ Jr, Klein PD, Adam E. Epidemiology of Helicobacter pylori in an asymptomatic population in the United States. Gastroenterology 1991;100:1495-1501.
77. Boren T, Falk P, Roth KA, Larson G, Normark S. Attachment of Helicobacter pylori to human gastric epithelium mediated by blood group antigens. Science 1993;262:1892-1895.
78. Ilver D, Arnqvist A, Ogren J, et al. Helicobacter pylori adhesin binding fucosylated histo-blood group antigens revealed by retagging. Science 1998;279:373-377.
79. Appelmelk BJ, Simoons-Smit I, Negrini R, et al. Potential role of molecular mimicry between Helicobacter pylori lipopolysaccharide and host Lewis blood group antigens in autoimmunity. Infect Immun 1996;64:2031-2040.
80. Monteiro MA, Chan KH, Rasko DA, et al. Simultaneous expression of type 1 and type 2 Lewis blood group antigens by Helicobacter pylori lipopolysaccharides. Molecular mimicry between H. pylori lipopolysaccharides and human gastric epithelial cell surface glycoforms. J Biol Chem 1998;273:11533-11543.
81. Galmiche A, Rassow J, Doye A, et al. The N-terminal 34 kDa fragment of Helicobacter pylori vacuolating cytotoxin targets mitochondria and induces cytochrome c release. EMBO J 2000;19:6361-6370.
82. Amieva MR, Vogelmann R, Covacci A, Tompkins LS, Nelson WJ, Falkow S. Disruption of the epithelial apical-junctional complex by Helicobacter pylori CagA. Science 2003;300:1430-1434.
83. Higashi H, Tsutsumi R, Muto S, et al. SHP-2 tyrosine phosphatase as an intracellular target of Helicobacter pylori CagA protein. Science 2002;295:683-686.
84. Negrini R, Savio A, Appelmelk BJ. Autoantibodies to gastric mucosa in Helicobacter pylori infection. Helicobacter 1997;2 (Suppl 1):S13-16.
85. Cao P, McClain MS, Forsyth MH, Cover TL. Extracellular release of antigenic proteins by Helicobacter pylori. Infect Immun 1998;66:2984-2986.
86. Bettaieb A, Oksenhendler E, Duedari N, Bierling P. Cross-reactive antibodies between HIV-gp120 and platelet gpIIIa (CD61) in HIV-related immune thrombocytopenic purpura. Clin Exp Immunol 1996;103:19-23.
87. Hohmann AW, Booth K, Peters V, Gordon DL, Comacchio RM. Common epitope on HIV p24 and human platelets. Lancet 1993;342:1274-1275.
88. Appelmelk BJ, van Die I, van Vliet SJ, Vandenbroucke-Grauls CMJE, Geijtenbeek TBH, van Kooyk Y. Carbohydrate profiling identifies new pathogens that interact with dendritic cell-specific ICAM-3 grabbing nonintegrin on dendritic cells. J Immunol 2003;170:1635-1639.
89. Voland P, Hafsi N, Zeitner M, Laforsch S, Wagner H, Prinz C. Antigenic properties of HpaA and Omp 18, two outer membrane proteins of Helicobacter pylori. Infect Immun 2003;71:3837-3843.
90. Ko GH, Park HB, Shin MK, et al. Monoclonal antibodies against Helicobacter pylori cross-react with human tissue. Helicobacter 1997;2:210-215.
91. Franceschi F, Christodoulides N, Kroll MH, Genta RM. Helicobacter pylori and idiopathic thrombocytopenic purpura. Ann Intern Med 2004;140:766-767.
92. Byrne MF, Kerrigan SW, Corcoran PA, et al. Helicobacter pylori binds von Willebrand factor and interacts with GPIb to induce platelet aggregation. Gastroenterology 2003;124:1846-1854.
93. Ianaro A, Ialenti A, Maffia P, et al. Anti-inflammatory activity of macrolide antibiotics. J Pharmacol Exp Ther 2000;292:156-163.